Pascual Sánchez-Juan, Elizabeth Valeriano-Lorenzo, Alicia Ruiz-González, Ana Belén Pastor, Hector Rodrigo Lara, Francisco López-González, María Ascensión Zea-Sevilla, Meritxell Valentí, Belen Frades, Paloma Ruiz, Laura Saiz, Iván Burgueño-García, Miguel Calero, Teodoro Del Ser, Alberto Rábano
Glial fibrillary acidic protein (GFAP), a proxy of astrocyte reactivity, has been proposed as biomarker of Alzheimer's disease. However, there is limited information about the correlation between blood biomarkers and post-mortem neuropathology. In a single-centre prospective clinicopathological cohort of 139 dementia patients, for which the time-frame between GFAP level determination and neuropathological assessment was exceptionally short (on average 139 days), we analysed this biomarker, measured at three time points, in relation to proxies of disease progression such as cognitive decline and brain weight...
April 18, 2024: Brain